INS and type 1 diabetes mellitus: A post‐hoc analysis of ADJUNCT ONE and ADJUNCT TWO trials, in fact, confirmed that patients with longer‐standing T1D and reduced beta‐cell reserve, as attested by undetectable c‐peptide levels, before starting GLP‐1RAs are more likely to discontinue the adjunctive treatment due to adverse effects or GLP‐1RA intolerance than individuals with residual insulin production.